OSA
MCID: APN008
MIFTS: 68

Apnea, Obstructive Sleep (OSA)

Categories: Blood diseases, Mental diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Apnea, Obstructive Sleep

MalaCards integrated aliases for Apnea, Obstructive Sleep:

Name: Apnea, Obstructive Sleep 57
Obstructive Sleep Apnea Syndrome 57 11 42 28 5 14
Obstructive Sleep Apnea 11 42 75 14 63 16
Sleep Apnea, Obstructive 42 43 71
Upper Airway Resistance Sleep Apnea Syndrome 42 71
Sleep Apnea/hypopnea Syndrome 57 42
Osas 57 42
Sahs 57 42
Osa 57 42
[osahs] - Obstructive Sleep Apnoea-Hypopnea Syndrome 33
Obstructive Sleep Apnoea Hypopnoea Syndrome 33
[sahs] - Sleep Apnoea-Hypopnea Syndrome 33
Obstructive Sleep Apnoea, Paediatric 33
Sleep Apnea Syndrome, Obstructive 42
Obstructive Sleep Apnoea Syndrome 33
Osa - [obstructive Sleep Apnoea] 33
Obstructive Sleep Apnoea, Adult 33
Sleep Apnea Hypopnea Syndrome 42
[sas] - Sleep Apnoea Syndrome 33
Sleep Apnea Obstructive 53
Sleep Apnea Syndromes 71
Sleep Apnoea Syndrome 33
Apnea, Obstructive 42
Obstructive Apnea 42
Sleep Apnoea Nos 33
Osa Syndrome 33
Osahs 42

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

Disease Ontology 11 DOID:0050848
OMIM® 57 107650
ICD9CM 34 327.23
MeSH 43 D020181
NCIt 49 C116337
SNOMED-CT 68 194441007
MedGen 40 C0520679
ICD11 33 1919233290
UMLS 71 C0037315 C0520679 C0751761

Summaries for Apnea, Obstructive Sleep

MedlinePlus Genetics: 42 Obstructive sleep apnea is a condition in which individuals experience pauses in breathing (apnea) during sleep, which are associated with partial or complete closure of the throat (pper airway). Complete closure can lead to apnea while partial closure allows breathing but decrease the intake of oxygen (hypopnea).Individuals with obstructive sleep apnea may experience interrupted sleep with frequent awakenings and loud snoring. Repeated pauses in breathing lead to episodes of lower-than-normal oxygen levels (hypoxemia) and a buildup of carbon dioxide (hypercapnia) in the bloodstream. Interrupted and poor quality sleep can lead to daytime sleepiness and fatigue, impaired attention and memory, headaches, depression, and sexual dysfunction. Daytime sleepiness leads to a higher risk of motor vehicle accidents in individuals with obstructive sleep apnea. Obstructive sleep apnea is also associated with an increased risk of developing insulin resistance, which is an inability to regulate blood sugar levels effectively; high blood pressure (hypertension); heart disease; and stroke.

MalaCards based summary: Apnea, Obstructive Sleep, also known as obstructive sleep apnea syndrome, is related to obesity-hypoventilation syndrome and acromegaly, and has symptoms including tremor, back pain and dyspnea. An important gene associated with Apnea, Obstructive Sleep is LEP (Leptin), and among its related pathways/superpathways are Metabolism of proteins and Signal Transduction. The drugs Montelukast and Opium have been mentioned in the context of this disorder. Affiliated tissues include heart, tongue and endothelial, and related phenotypes are anosmia and obstructive sleep apnea

PubMed Health : 63 Obstructive sleep apnea: We all know what it is like to feel tired after a sleepless night because of things like noise, worries or stress. But what if you do actually get enough sleep and still feel absolutely beat the next morning? This is normal for many people with obstructive sleep apnea (OSA): They do not get enough air while they are sleeping (but do not usually notice this), have breathing pauses, and feel very sleepy during the day. In the long term, this increases their risk of developing other illnesses and can have a huge effect on their quality of life.

Disease Ontology: 11 A sleep apnea that is characterized by repeated collapse and obstruction of the upper airway during sleep, which results in reduced airflow (hypopnea) or complete airflow cessation (apnea), oxygen desaturation, and arousals from sleep.

OMIM®: 57 Obstructive sleep apnea is a common, chronic, complex disease associated with serious cardiovascular and neuropsychologic sequelae and with substantial social and economic costs (Palmer et al., 2003). (107650) (Updated 08-Dec-2022)

Wikipedia: 75 Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and is characterized... more...

Related Diseases for Apnea, Obstructive Sleep

Diseases related to Apnea, Obstructive Sleep via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1682)
# Related Disease Score Top Affiliating Genes
1 obesity-hypoventilation syndrome 32.2 LEP IL6 ADIPOQ
2 acromegaly 31.4 LEP INS GHRL ADIPOQ
3 hypercholesterolemia, familial, 1 31.3 INS CRP APOE ACE
4 dermatitis 31.1 TNF IL6 IL1B CXCL8
5 prediabetes syndrome 31.0 LEP INS GHRL CRP ADIPOQ
6 actinomycosis 31.0 TNF CRP ALB
7 graves ophthalmopathy 31.0 TNF IL6 IL1B
8 headache 31.0 TNF HTR2A CXCL8 ALB
9 vascular dementia 31.0 TNF INS IL6 IL1B APOE ACE
10 eclampsia 31.0 TNF REN IL6 EDN1 ALB AGT
11 insulin-like growth factor i 31.0 LEP INS IL6 GHRL
12 abdominal obesity-metabolic syndrome 1 31.0 LEP INS GHRL ADIPOQ
13 hypertrophic cardiomyopathy 31.0 TNF REN MIR486-1 INS IL6 EDN1
14 mitral valve insufficiency 31.0 REN CRP ALB ACE
15 eating disorder 31.0 LEP INS HTR2A HCRT GHRL
16 tricuspid valve insufficiency 31.0 REN EDN1 CRP ALB ACE
17 autonomic neuropathy 30.9 REN INS ALB
18 esophagitis 30.9 TNF IL6 IL1B CXCL8
19 post-traumatic stress disorder 30.9 IL6 IL1B HTR2A HCRT CRP
20 normal pressure hydrocephalus 30.9 HCRT APOE ALB
21 autoimmune disease 30.9 TNF INS IL6 IL1B CRP
22 bronchiolitis 30.9 TNF IL6 IL1B CXCL8 CRP
23 acute asthma 30.9 TNF IL6 CXCL8
24 non-alcoholic steatohepatitis 30.9 TNF LEP INS IL6 IL1B ALB
25 acute kidney failure 30.9 REN IL6 ALB ACE
26 retinal disease 30.8 MIR486-1 INS IL6 ALB
27 nutritional deficiency disease 30.8 LEP IL6 GHRL CRP ALB ADIPOQ
28 diabetic autonomic neuropathy 30.8 REN INS ALB ACE
29 pulmonary disease, chronic obstructive 30.8 TNF MIRLET7D IL6 IL1B CXCL8 CRP
30 juvenile rheumatoid arthritis 30.8 TNF IL6 IL1B CRP
31 renal artery atheroma 30.8 REN ALB ACE
32 amyloidosis 30.8 TNF INS IL6 IL1B CRP APOE
33 periodontitis, chronic 30.8 IL6 IL1B
34 glucose intolerance 30.8 TNF LEP INS IL6 GHRL CRP
35 fibromyalgia 30.8 TNF LEP INS IL6 IL1B HTR2A
36 familial partial lipodystrophy 30.8 LEP INS ADIPOQ
37 amenorrhea 30.8 LEP INS GHRL ADIPOQ
38 gout 30.8 TNF INS IL6 IL1B CXCL8 CRP
39 nerve compression syndrome 30.8 INS IL6 CRP ALB
40 hyperinsulinism 30.8 LEP INS GHRL EDN1 ADIPOQ
41 radiculopathy 30.8 IL6 CXCL8 CRP
42 prostatic hypertrophy 30.8 INS CRP ALB ACE
43 arthropathy 30.8 TNF IL6 IL1B CRP
44 aortic disease 30.8 REN MIR486-1 IL6 IL1B CRP APOE
45 autism spectrum disorder 30.8 TNF LEP IL6 IL1B GHRL ADIPOQ
46 dysthymic disorder 30.8 INS IL6 HTR2A HCRT CRP
47 microvascular complications of diabetes 3 30.7 REN INS ALB ACE
48 hemoglobinopathy 30.7 INS IL6 CRP ALB
49 inflammatory bowel disease 1 30.7 TNF IL6 IL1B
50 systemic scleroderma 30.7 TNF IL6 IL1B EDN1 CXCL8 CRP

Graphical network of the top 20 diseases related to Apnea, Obstructive Sleep:



Diseases related to Apnea, Obstructive Sleep

Symptoms & Phenotypes for Apnea, Obstructive Sleep

Human phenotypes related to Apnea, Obstructive Sleep:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anosmia 30 HP:0000458
2 obstructive sleep apnea 30 HP:0002870
3 excessive daytime somnolence 30 HP:0001262
4 focal impaired awareness seizure 30 HP:0002384
5 snoring 30 HP:0025267

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neuro:
anosmia
partial complex seizures

Misc:
hypersomnolence
restless movements during sleep

Resp:
obstructive sleep apnea
snoring

Clinical features from OMIM®:

107650 (Updated 08-Dec-2022)

UMLS symptoms related to Apnea, Obstructive Sleep:


tremor; back pain; dyspnea; apnea; headache; syncope; excessive daytime somnolence; pain; wheezing; chronic pain; sciatica; snoring; sleep disturbances; seizures; cheyne-stokes respiration; coughing; vertigo/dizziness; sleeplessness; labored breathing; insomnia with sleep apnea, unspecified; hypersomnia with sleep apnea, unspecified; disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Apnea, Obstructive Sleep:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ACE ADIPOQ AGT ALB APOE CRP
2 muscle MP:0005369 10.31 ADIPOQ AGT ALB APOE EDN1 HCRT
3 nervous system MP:0003631 10.3 ADIPOQ AGT APOE EDN1 HCRT HIF1A
4 renal/urinary system MP:0005367 10.25 ACE ADIPOQ AGT ALB APOE EDN1
5 cardiovascular system MP:0005385 10.2 ACE ADIPOQ AGT ALB APOE CRP
6 liver/biliary system MP:0005370 10.18 ACE ADIPOQ AGT ALB APOE HIF1A
7 endocrine/exocrine gland MP:0005379 10.18 ACE ADIPOQ ALB APOE EDN1 GHRL
8 adipose tissue MP:0005375 10.16 ACE ADIPOQ AGT APOE GHRL HIF1A
9 neoplasm MP:0002006 10.14 ACE ADIPOQ ALB HIF1A IL1B IL6
10 digestive/alimentary MP:0005381 10.07 ALB APOE EDN1 GHRL HIF1A HTR2A
11 behavior/neurological MP:0005386 10.07 ACE ADIPOQ AGT APOE GHRL HCRT
12 immune system MP:0005387 9.97 ACE ADIPOQ AGT ALB APOE CRP
13 skeleton MP:0005390 9.65 ADIPOQ APOE EDN1 HIF1A HTR2A IL1B
14 mortality/aging MP:0010768 9.47 ACE ADIPOQ AGT ALB APOE EDN1

Drugs & Therapeutics for Apnea, Obstructive Sleep

PubMed Health treatment related to Apnea, Obstructive Sleep: 63

If you are very overweight , losing weight can help improve sleep apnea . There are also many treatment options that aim to relieve sleep apnea. These include machines that support breathing during the night, surgery , and special aids such as mouth guards. Some of these treatments have been scientifically proven to help people with sleep apnea. Medication is currently not used for the treatment of sleep apnea. There is no scientific evidence that the available medications work. The most effective treatment for severe sleep apnea is called CPAP therapy . CPAP stands for “continuous positive airway pressure.” In this treatment approach, air is taken from the immediate surroundings and blown into your airways at night using low pressure. While you sleep, you wear a breathing mask that is connected to a machine called a respirator. The pressure keeps the upper airways open. People who use this machine have fewer breathing pauses, or even none at all. This can noticeably improve the symptoms such as tiredness during the day. Common side effects include a dry throat and an irritated, sometimes blocked nose .

Drugs for Apnea, Obstructive Sleep (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 398)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Opium Approved, Illicit Phase 4 8008-60-4
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Nitric Oxide Approved Phase 4 10102-43-9 145068
6
Acetazolamide Approved, Vet_approved Phase 4 59-66-5, 1424-27-7 1986
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
9
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
10
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
11
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
12
Sodium oxybate Approved Phase 4 502-85-2 23663870
13
Desflurane Approved Phase 4 57041-67-5 42113
14
Losartan Approved Phase 4 114798-26-4 3961
15
Donepezil Approved Phase 4 120014-06-4 3152
16
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
17
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
18
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
19
Glycopyrronium Approved, Investigational, Vet_approved Phase 4 596-51-0, 740028-90-4 3494
20
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
21
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
22
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
23
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
24
Adalimumab Approved, Experimental Phase 4 331731-18-1
25
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
26
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
27
Eplerenone Approved Phase 4 107724-20-9 443872
28
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
29
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
30
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
31
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
32
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
33
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
34
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
35
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
36
Zolpidem Approved Phase 4 82626-48-0 5732
37
Promethazine Approved, Investigational Phase 4 60-87-7 4927
38
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
39
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
40
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
41
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
42
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456 5824
43
Phenylephrine Approved Phase 4 59-42-7 6041
44
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
45
Carbidopa Approved Phase 4 28860-95-9 34359 38101
46
Levodopa Approved Phase 4 59-92-7, 63-84-3 6047
47
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
48
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
49
Finasteride Approved Phase 4 98319-26-7 57363
50
Buspirone Approved, Investigational Phase 4 36505-84-7 2477

Interventional clinical trials:

(show top 50) (show all 2272)
# Name Status NCT ID Phase Drugs
1 Comparison of the Pentax AWS® With the Macintosh Laryngoscope for Tracheal Intubation in Patients With Obstructive Sleep Apnea Syndrome: a Randomized Comparative Study Unknown status NCT01428570 Phase 4
2 Cost-utility Study of CPAP Treatment in Obstructive Sleep Apnea Patients Unknown status NCT01590420 Phase 4
3 Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients Unknown status NCT01524510 Phase 4
4 Acetazolamide as add-on Therapy to Obstructive Sleep Apnea Surgery (ACTOS): a Parallel-group, Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT04227093 Phase 4 Acetazolamide;Placebo
5 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
6 Randomised Monocentric -Controlled Study to Evaluate the Efficacy and Stability of Dexmedetomidine Sedation Compared to Propofol Sedation in the Routinely Diagnostic Examination: Drug Induced Sleep Endoscopy Unknown status NCT03892122 Phase 4 Propofol Fresenius;Dexmedetomidine
7 A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA Unknown status NCT02724865 Phase 4
8 Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study Unknown status NCT02325089 Phase 4
9 Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study Unknown status NCT00912457 Phase 4 donepezil;placebo
10 Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients. Unknown status NCT01771406 Phase 4 Nebivolol
11 Blood Pressure Reduction Induced by Continuous Positive Airway Pressure (CPAP) in Sleep Apnea Patients at High Cardiovascular Risk : A Randomized Controlled Trial Comparing Usual CPAP Care Versus a Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform Unknown status NCT01505959 Phase 4
12 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
13 Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability Unknown status NCT03890939 Phase 4
14 Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing Unknown status NCT00299910 Phase 4 Montelukast
15 Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption Unknown status NCT02371473 Phase 4 Acetazolamide-placebo;Placebo-acetazolamide
16 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
17 The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
18 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving Continuous Positive Airway Pressure (CPAP) Compliance in Low Cardiovascular Risk Sleep Apnea Patients Unknown status NCT01796769 Phase 4
19 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
20 The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome Completed NCT01699126 Phase 4 Statin
21 Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension. Completed NCT00409487 Phase 4 Valsartant treatment
22 Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial Completed NCT02425202 Phase 4 Ketamine
23 Effect of Combined Use of Tolterodine and Continuous Positive Airway Pressure vs Continuous Positive Airway Pressure Only Treatment on Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome: A Randomized Clinical Trial Completed NCT05250245 Phase 4 Tolterodine Tartrate 4 MG
24 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
25 Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome Completed NCT00603044 Phase 4 fluticasone furoate
26 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
27 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
28 Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS). Completed NCT01508754 Phase 4
29 Differential Effects of Chronic Treatment of OSAS by CPAP and SOMNOsmart2 on Norepinephrine and Blood Pressure Completed NCT00633711 Phase 4
30 Does Nasal Decongestion Improve Obstructive Sleep Apnea ? Completed NCT00630474 Phase 4 xylometazoline
31 Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
32 PROMAD : Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Completed NCT01532050 Phase 4
33 SASQT: SensAwake™ Sleep Quality Trial A Study to Test the Efficacy of the SensAwake™ Modification to Automatically Titrating Continuous Positive Airway Pressure to Reduce Wake After Sleep Onset in Patients With Moderate to Severe Obstructive Sleep Apnea. Completed NCT00811213 Phase 4
34 Cardiovascular Impact of Obstructive Sleep Apnea in Normotensive Patients and the Effects of Continuous Positive Airway Pressure Completed NCT00741520 Phase 4
35 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function Completed NCT04789174 Phase 4 Solriamfetol;Placebo
36 Respiratory Impact of Short Life Agents Used in Balanced Anesthesia on Patients Suffering or Suspected of Obstructive Sleep Apnea (OSA) Syndrome Completed NCT02717780 Phase 4 Fentanyl and sevoflurane;Remifentanil and desflurane
37 Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment Completed NCT00701428 Phase 4 Losartan
38 The Impact of Arousal Threshold in Obstructive Sleep Apnea: Donepezil's Effects on the Arousal Threshold and on the Apnea Hypopnea Index Completed NCT02264353 Phase 4 Donepezil;placebo
39 A Blinded Crossover Study of the 24 Hour Blood Pressure Response to Treatment of Obstructive Sleep Apnea Associated Hypertension With Nebivolol or Hydrochlorothiazide Completed NCT02710071 Phase 4 Nebivolol;Hydrochlorothiazide
40 Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Completed NCT00711516 Phase 4 Armodafinil;Placebo
41 Effects of Continuous Positive Airway Pressure (CPAP) on Early Signs of Atherosclerosis in Patients With Obstructive Sleep Apnea: a Randomized Study Completed NCT00400543 Phase 4
42 A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension Completed NCT02699125 Phase 4 Guanfacine;Hydrochlorothiazide
43 Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial Completed NCT03679611 Phase 4 Sugammadex Sodium;Neostigmine
44 The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea Completed NCT02714400 Phase 4 Venlafaxine;Placebo
45 Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea Completed NCT00729963 Phase 4 Sibutramine
46 The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression Completed NCT04162743 Phase 4 Trazodone;Placebo oral tablet
47 Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome: A Randomized Study Completed NCT02295202 Phase 4
48 Dexmedetomidine Added to Propofol for Drug Induced Sleep Endoscopy in Adult Patients With Obstructive Sleep Apnea: A Prospective Randomized Controlled Trial Completed NCT03091894 Phase 4 Propofol;Dexmedetomidine
49 Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder Completed NCT00518986 Phase 4 armodafinil;placebo
50 Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls Completed NCT00410085 Phase 4 L-NMMA (N-mono.methyl-L-arginine)

Search NIH Clinical Center for Apnea, Obstructive Sleep

Cochrane evidence based reviews: sleep apnea, obstructive

Genetic Tests for Apnea, Obstructive Sleep

Genetic tests related to Apnea, Obstructive Sleep:

# Genetic test Affiliating Genes
1 Obstructive Sleep Apnea Syndrome 28

Anatomical Context for Apnea, Obstructive Sleep

Organs/tissues related to Apnea, Obstructive Sleep:

MalaCards : Heart, Tongue, Endothelial, Brain, Spinal Cord, Lung, Tonsil

Publications for Apnea, Obstructive Sleep

Articles related to Apnea, Obstructive Sleep:

(show top 50) (show all 31419)
# Title Authors PMID Year
1
APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. 62 57
17636061 2007
2
Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. 62 57
16116137 2005
3
APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. 62 57
15326239 2004
4
Serum amyloid a in obstructive sleep apnea. 62 57
12952844 2003
5
A whole-genome scan for obstructive sleep apnea and obesity. 62 57
12506338 2003
6
The genetics of sleep apnea. 62 57
12531037 2000
7
Familial aggregates in obstructive sleep apnea syndrome. 62 57
7781344 1995
8
Is the sleep apnoea/hypopnoea syndrome inherited? 62 57
8153920 1993
9
Studies in the genetics of obstructive sleep apnea. Familial aggregation of symptoms associated with sleep-related breathing disturbances. 62 57
1736754 1992
10
Atrial flutter associated with obstructive sleep apnea syndrome. A case report. 62 57
7352787 1980
11
Familial obstructive sleep apnea. 62 57
759949 1979
12
Obstructive sleep apnea in Georgia family: is it hereditary? 62 57
712965 1978
13
Obstructive sleep apnea in family members. 62 57
211413 1978
14
Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. 57
12003609 2002
15
Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. 57
11401610 2001
16
Familial predisposition to snoring. 57
8153952 1994
17
Familial 'sleep apnea plus' syndrome: report of a family. 57
3257550 1988
18
Sleeping and breathing. 57
692617 1978
19
The sleep apnea syndromes. 57
180875 1976
20
[Roles of hypertension and serum leptin in obstructive sleep apnea hypopnea syndrome]. 53 62
20450544 2010
21
[Study of the level of adiponectin in obstructive sleep apnea-hypopnea syndrome patients]. 53 62
20518291 2010
22
Plasma adiponectin level and sleep structures in children with Prader-Willi syndrome. 53 62
19912511 2010
23
Effects of nasal continuous positive airway pressure treatment on oxidative stress and adiponectin levels in obese patients with obstructive sleep apnea. 53 62
19590157 2010
24
Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. 53 62
19127383 2009
25
Mediators of sympathetic activation in metabolic syndrome obesity. 53 62
18959829 2008
26
Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. 53 62
19090328 2008
27
The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. 53 62
18812827 2008
28
Airway inflammation in obstructive sleep apnea: is leptin the missing link? 53 62
18606530 2008
29
Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. 53 62
18365276 2008
30
Re: Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. 53 62
18574304 2008
31
Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. 53 62
18198351 2008
32
[Diagnostic values of serum orexin-A levels in children with obstructive sleep apnea-hypopnea syndrome]. 53 62
19099733 2008
33
Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. 53 62
17989154 2008
34
Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. 53 62
18981626 2008
35
Effect of serum leptin levels on hypercapnic ventilatory response in obstructive sleep apnea. 53 62
18073454 2008
36
Frequency of distribution of leptin receptor gene polymorphism in obstructive sleep apnea patients. 53 62
18204169 2007
37
Leptin measurement in urine is a reliable method of monitoring its secretion in patients with obstructive sleep apnea syndrome. 53 62
18204121 2007
38
Obstructive sleep apnea, daytime sleepiness, and type 2 diabetes. 53 62
17570878 2007
39
Reduced levels of adiponectin in sleep apnea syndrome. 53 62
17033258 2006
40
[A study of the level of serum leptin in patients with obstructive sleep apnea-hypopnea syndrome and obesity and patients with normal body mass]. 53 62
16836068 2006
41
Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. 53 62
16205042 2006
42
[The influence of 3 weeks therapy with continuous positive airway pressure on serum leptin and homocysteine concentration in patients with obstructive sleep apnea syndrome]. 53 62
17175979 2006
43
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. 53 62
16088283 2005
44
[Serum leptin concentration and sympathetic activation estimated on the adrenaline and noradrenaline serum concentration in patients with obstructive sleep apnea]. 53 62
16454443 2005
45
[The changes and implications of plasma orexin-A levels in patients with obstructive sleep apnea-hypopnea syndrome]. 53 62
16008971 2005
46
[Serum leptin level in patients with obstructive sleep apnea-hypopnea syndrome]. 53 62
16008254 2005
47
Low plasma orexin-A levels were improved by continuous positive airway pressure treatment in patients with severe obstructive sleep apnea-hypopnea syndrome. 53 62
15764751 2005
48
Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hypopnea syndrome. 53 62
15764749 2005
49
Fat accumulation, leptin, and hypercapnia in obstructive sleep apnea-hypopnea syndrome. 53 62
15705994 2005
50
Interactions between obstructive sleep apnea and the metabolic syndrome. 53 62
15663918 2005

Variations for Apnea, Obstructive Sleep

ClinVar genetic disease variations for Apnea, Obstructive Sleep:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RYR1 NM_000540.3(RYR1):c.10097G>T (p.Arg3366Leu) SNV Uncertain Significance
598974 rs137932199 GRCh37: 19:39009932-39009932
GRCh38: 19:38519292-38519292
2 SYNE2 NM_182914.3(SYNE2):c.19624G>T (p.Gly6542Trp) SNV Uncertain Significance
598975 rs746433383 GRCh37: 14:64685197-64685197
GRCh38: 14:64218479-64218479

Expression for Apnea, Obstructive Sleep

Search GEO for disease gene expression data for Apnea, Obstructive Sleep.

Pathways for Apnea, Obstructive Sleep

Pathways related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 REN LEP INS IL6 HIF1A GHRL
2 13.74 AGT APOE CXCL8 EDN1 GHRL HCRT
3
Show member pathways
13.03 ACE AGT HIF1A IL6 INS REN
4
Show member pathways
12.84 TNF LEP INS IL6 ADIPOQ
5
Show member pathways
12.81 TNF INS IL6 IL1B APOE
6
Show member pathways
12.6 TNF IL6 IL1B EDN1 CXCL8
7
Show member pathways
12.49 TNF IL6 IL1B CXCL8
8
Show member pathways
12.39 CXCL8 IL1B IL6 TNF
9
Show member pathways
12.29 TNF IL6 IL1B CXCL8
10
Show member pathways
12.11 REN LEP INS GHRL AGT ACE
11 12 CXCL8 HIF1A HTR2A IL1B IL6 TNF
12
Show member pathways
11.99 TNF REN AGT ACE
13 11.99 TNF LEP IL6 IL1B CXCL8
14 11.96 TNF IL6 IL1B HIF1A CXCL8
15 11.94 INS IL6 IL1B CXCL8
16 11.89 LEP INS IL6 ADIPOQ
17
Show member pathways
11.79 CRP CXCL8 HIF1A IL6
18 11.77 TNF IL6 IL1B CXCL8
19 11.73 TNF IL6 IL1B
20 11.71 TNF IL6 CRP
21 11.69 IL6 IL1B HIF1A
22
Show member pathways
11.68 TNF IL6 IL1B CXCL8
23 11.66 LEP HIF1A EDN1
24 11.64 TNF IL6 CXCL8
25 11.64 TNF IL6 IL1B
26 11.6 IL6 HIF1A EDN1 CXCL8 AGT
27 11.59 INS IL6 CXCL8
28 11.57 IL6 HIF1A CXCL8
29 11.54 TNF IL6 CXCL8
30 11.54 TNF IL6 IL1B CXCL8
31 11.51 TNF IL6 IL1B APOE
32
Show member pathways
11.46 TNF IL1B AGT
33 11.36 TNF IL6 IL1B
34 11.35 TNF IL6 IL1B EDN1 CXCL8
35 11.32 IL1B IL6 TNF
36 11.28 TNF LEP INS IL6 HIF1A AGT
37 11.27 TNF IL6 IL1B
38 11.27 CXCL8 IL1B IL6 TNF
39
Show member pathways
11.26 CRP EDN1 HIF1A LEP
40 11.23 TNF IL6 CXCL8
41 11.2 TNF IL6 IL1B CXCL8
42 11.08 LEP INS GHRL
43 11.08 TNF LEP IL6 ADIPOQ
44 11.02 TNF LEP INS IL6 ADIPOQ
45 10.84 TNF IL6 CXCL8 CRP
46 10.75 IL6 CXCL8 AGT
47
Show member pathways
10.39 TNF IL6 CXCL8

GO Terms for Apnea, Obstructive Sleep

Cellular components related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.16 ACE ADIPOQ AGT ALB APOE CRP
2 extracellular space GO:0005615 9.83 ACE ADIPOQ AGT ALB APOE CRP

Biological processes related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.5 CRP CXCL8 HIF1A IL1B IL6 INS
2 positive regulation of cell population proliferation GO:0008284 10.45 AGT EDN1 HTR2A IL1B IL6 INS
3 negative regulation of gene expression GO:0010629 10.36 TNF INS HIF1A EDN1 CXCL8 APOE
4 positive regulation of MAPK cascade GO:0043410 10.35 TNF LEP INS IL6 GHRL
5 defense response to Gram-positive bacterium GO:0050830 10.33 TNF IL6 IL1B CRP
6 positive regulation of DNA-binding transcription factor activity GO:0051091 10.33 EDN1 IL1B IL6 TNF
7 positive regulation of cytosolic calcium ion concentration GO:0007204 10.33 HTR2A HCRT GHRL EDN1 AGT
8 positive regulation of inflammatory response GO:0050729 10.32 ACE AGT TNF IL1B
9 positive regulation of interleukin-6 production GO:0032755 10.31 TNF LEP IL6 IL1B
10 positive regulation of cold-induced thermogenesis GO:0120162 10.31 LEP HCRT GHRL ADIPOQ
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.3 IL6 HTR2A AGT ADIPOQ
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.29 TNF LEP INS AGT
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.29 TNF INS IL6 IL1B AGT
14 positive regulation of MAP kinase activity GO:0043406 10.27 TNF IL1B HTR2A EDN1
15 response to lipopolysaccharide GO:0032496 10.27 TNF REN IL1B EDN1 ACE
16 response to xenobiotic stimulus GO:0009410 10.26 TNF REN HTR2A EDN1 ADIPOQ ACE
17 cellular response to xenobiotic stimulus GO:0071466 10.24 ADIPOQ EDN1 IL1B REN
18 glucose homeostasis GO:0042593 10.22 ADIPOQ HIF1A IL6 INS LEP
19 response to hypoxia GO:0001666 10.22 ACE ADIPOQ EDN1 HIF1A LEP TNF
20 acute-phase response GO:0006953 10.21 INS IL6 CRP
21 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.2 TNF LEP IL6
22 negative regulation of endothelial cell proliferation GO:0001937 10.2 TNF GHRL APOE
23 regulation of insulin secretion GO:0050796 10.2 IL1B IL6 LEP TNF
24 negative regulation of MAP kinase activity GO:0043407 10.19 IL1B APOE AGT ADIPOQ
25 positive regulation of vascular endothelial growth factor production GO:0010575 10.18 IL6 IL1B HIF1A
26 eating behavior GO:0042755 10.18 LEP HCRT ACE
27 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.17 HIF1A IL6 TNF
28 negative regulation of neurogenesis GO:0050768 10.17 TNF IL6 IL1B
29 positive regulation of insulin receptor signaling pathway GO:0046628 10.16 LEP INS AGT
30 positive regulation of nitric oxide biosynthetic process GO:0045429 10.15 TNF IL1B EDN1 AGT
31 regulation of blood pressure GO:0008217 10.15 REN LEP EDN1 AGT ACE
32 positive regulation of glycolytic process GO:0045821 10.14 INS HTR2A HIF1A
33 regulation of vasoconstriction GO:0019229 10.14 EDN1 AGT ACE
34 vasodilation GO:0042311 10.14 TNF INS APOE AGT
35 positive regulation of glial cell proliferation GO:0060252 10.13 TNF IL6 IL1B
36 positive regulation of mitotic nuclear division GO:0045840 10.13 EDN1 IL1B INS TNF
37 positive regulation of interleukin-8 production GO:0032757 10.13 TNF LEP IL6 IL1B ADIPOQ
38 negative regulation of lipid catabolic process GO:0050995 10.12 TNF INS IL1B
39 positive regulation of chemokine production GO:0032722 10.12 TNF IL6 IL1B HIF1A
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.1 APOE IL1B TNF
41 negative regulation of glucose import GO:0046325 10.09 TNF LEP ACE
42 artery smooth muscle contraction GO:0014824 10.07 HTR2A EDN1 AGT
43 positive regulation of cytokine production GO:0001819 10.06 TNF LEP INS IL1B AGT
44 positive regulation of fever generation GO:0031622 10.03 TNF IL1B
45 positive regulation of neuroinflammatory response GO:0150078 10.03 TNF IL6 IL1B
46 positive regulation of dendritic spine maintenance GO:1902952 10.02 INS APOE
47 sequestering of triglyceride GO:0030730 10.02 TNF IL1B
48 regulation of transmission of nerve impulse GO:0051969 10.02 GHRL AGT
49 glucose metabolic process GO:0006006 10.02 TNF LEP INS GHRL ADIPOQ
50 blood vessel diameter maintenance GO:0097746 10.01 EDN1 AGT ACE

Molecular functions related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.85 TNF REN LEP IL6 EDN1 APOE
2 cytokine activity GO:0005125 9.7 TNF IL6 IL1B EDN1 CXCL8 ADIPOQ
3 hormone activity GO:0005179 9.36 LEP INS GHRL EDN1 AGT ADIPOQ

Sources for Apnea, Obstructive Sleep

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....